Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
7.52
+0.67 (9.71%)
At close: Aug 19, 2026, 4:00 PM EDT
7.66
+0.15 (1.93%)
After-hours: Aug 19, 2026, 4:52 PM EDT
Upstream Bio Market Cap
Upstream Bio has a market cap or net worth of $411.6 million as of August 19, 2026. Its market cap has decreased by -57.63% in one year.
Market Cap
411.60M
Enterprise Value
151.25M
1-Year Change
-57.63%
Ranking
Category
Stock Price
$7.52
ChartMarket Cap Chart
Since the IPO on October 11, 2024, Upstream Bio's market cap has increased from $393.35M to $411.60M, an increase of 4.64%. That is a compound annual growth rate of 2.48%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 19, 2026 | 411.60M | -71.95% |
| Dec 31, 2025 | 1.47B | 66.51% |
| Dec 31, 2024 | 881.13M | 124.01% |
| Oct 11, 2024 | 393.35M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Atea Pharmaceuticals | 417.06M |
| Compass Therapeutics | 416.00M |
| Fennec Pharmaceuticals | 413.44M |
| Lexeo Therapeutics | 406.11M |
| EyePoint | 402.61M |
| Foghorn Therapeutics | 394.69M |
| Scribe Therapeutics | 390.68M |
| Palisade Bio | 377.30M |